Expertise in
9
conditions

Kang-moon M. Lee

St. Vincent's Hospital, 
Suwon, KR 
Expertise in
9
conditions
St. Vincent's Hospital, 
Suwon, KR 

Overview

Kang-moon Lee practices practicing medicine in Suwon, Republic of Korea.

Lee is highly rated in 9 conditions, according to our data. Their clinical expertise encompasses Hemorrhagic Proctocolitis, Ulcerative Colitis, Colitis, Colonoscopy, and Endoscopy.

They are actively involved in clinical research, co-authoring 155 peer reviewed articles and participating in 2 clinical trials.

Locations

St. Vincent's Hospital, Suwon, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: May 13, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
View 1 Less Clinical Trial

155 Total Publications

Treatment persistence after switching between anti-tumor necrosis factor agents and tofacitinib in ulcerative colitis: A nationwide claims-based cohort study in South Korea.
Treatment persistence after switching between anti-tumor necrosis factor agents and tofacitinib in ulcerative colitis: A nationwide claims-based cohort study in South Korea.
Journal: Therapeutic advances in gastroenterology
Published: May 19, 2026

Frequently Asked Questions about Kang-moon M. Lee

Is Kang-moon M. Lee a top-rated expert for Hemorrhagic Proctocolitis?

MediFind is an objective health platform that identifies experts based on real-world data. Kang-moon M. Lee is classified as an Distinguished expert for Hemorrhagic Proctocolitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Kang-moon M. Lee participate in research or clinical trials?

Yes. Kang-moon M. Lee has published 155 articles and abstracts on conditions like Hemorrhagic Proctocolitis. You can view a list of Kang-moon M. Lee's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Lee's expertise for a condition
ConditionClose
    View All 12 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile